Application of blood flow resistance index plus the risk of malignant index in preoperative assessment of ovarian neoplasm
10.3760/cma.j.issn.1008-6315.2013.11.004
- VernacularTitle:阻力指数和搏动指数联合恶性危险指数对卵巢肿瘤术前评估的价值
- Author:
Zhimin HOU
;
Xiuying DU
- Publication Type:Journal Article
- Keywords:
Ovarian neoplasm;
Color Doppler ultrasound;
Resistance index;
Pulse index;
Risk of malignant index
- From:
Clinical Medicine of China
2013;29(11):1129-1132
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the possibility of blood flow resistance index (RI),pulse index (PI) plus the risk of malignant index (RMI) in preoperative diagnosis of ovarian neoplasm.Methods Four hundred and sixty-eight women with ovarian tumor,30 years or older,were enrolled in current study from January 2007 to December 2012 in the People's Hospital of Tianjin.Among them,127 were with malignant ovarian tumors and 341 with benign ovarian tumors.They were retrospectively prospective assessed by RI + PI,RMI,and RI + PI combine with RMI.Results The value of RI,PI of malignant ovarian tumors group were lower than those of benign ovarian tumors group ((0.41 ± 0.08) vs (0.68 ± 0.15),t =28.83,P ＜ 0.01 ; (0.82 ± 0.24) vs (1.67 ±0.71),t =22.26,P ＜0.01).RMI of malignant ovarian tumors group was (269.7 ±41.2),higher than that of benign ovarian tumors group(25.6 ± 11.4,t =107.55,P ＜0.01).The indices of RI ＜0.40 and/or PI ＜1.00,RMI ＞ 200 were served as the critical biomarker respectively.Histopathological examination result was conducted and considered as gold standard for identifying patients with ovarian cancer pelvic masses.The sensitivity of RI,PI plus RMI was 92.57％,higher than that used by RI and PI (81.02％) or RMI only (84.21％),and the difference was significant (P ＜ 0.05).The sensitivity,specificity,positive and negative predictive values of the combined index of RI,PI adding to RMI were all higher than 90％.Conclusion The combined index of RI,PI plus RMI was proved to enhance the diagnostic accuracy regarding of the preoperative diagnosis of benign or malignant ovarian tumors.
